Z. Lim

G. Mufti, R. Ireland, H. de Lavallade, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML

G. Mufti, R. Brand, Z. Lim, 2010, Bone Marrow Transplantation.

Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.

G. Mufti, R. Brand, D. Niederwieser, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sarcoidosis as an unusual cause of hepatic dysfunction following reduced intensity conditioned allogeneic stem cell transplantation

J. Salisbury, G. Mufti, Z. Lim, 2007, Bone Marrow Transplantation.

Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience.

G. Mufti, K. Ramasamy, S. Mahmood, 2011, Clinical lymphoma, myeloma & leukemia.

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.

G. Mufti, J. Maciejewski, N. Lea, 2010, Blood.

Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.

G. Mufti, N. Russell, R. Ireland, 2011, Blood.

Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab

G. Mufti, Z. Lim, L. Pearce, 2010, British journal of haematology.

Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative

G. Mufti, Z. Lim, L. Pearce, 2008, Bone Marrow Transplantation.

Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival

G. Mufti, R. Brand, Z. Lim, 2007, Bone Marrow Transplantation.

Disseminated herpes virus (HSV-2) infection with rhabdomyolysis and hemophagocytic lymphohistiocytosis in a patient with bone marrow failure syndrome

J. Salisbury, G. Mufti, K. Ramasamy, 2006, Annals of Hematology.

Outcomes of alemtuzumab‐based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes

G. Mufti, B. Czepulkowski, Z. Lim, 2006, British journal of haematology.

Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation.

G. Mufti, M. Zuckerman, D. Marks, 2009, Leukemia research.

Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.

G. Mufti, N. Lea, Z. Lim, 2011, Leukemia research.

T‐cell lymphoblastic lymphoma presenting as an intra‐muscular mass

S. Gupta, J. Salisbury, G. Mufti, 2006, British journal of haematology.

Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab

G. Mufti, J. Madrigal, G. Lombardi, 2009, Haematologica.

Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.

G. Mufti, R. Marcus, R. Ireland, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

IL‐17‐producing CD4+ T cells, pro‐inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome

G. Mufti, F. Farzaneh, G. Lombardi, 2009, British journal of haematology.

National, Retrospective, Multi-Centre Comparison of Alemtuzumab- Versus ATG-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Aplastic Anemia: A Study From the British Society for Blood and Marrow Transplantation (BSBMT) (CTCR 09-03)

G. Mufti, J. Snowden, G. Cook, 2011 .

Life coaching following haematopoietic stem cell transplantation: a mixed-method investigation of feasibility and acceptability.

G. Mufti, E. Ream, Z. Lim, 2015, European journal of cancer care.

MOBILISATION FAILURE IS PREDICTIVE OF POOR OVERALL SURVIVAL AFTER AUTOLOGOUS TRANSPLANTATION

G. Mufti, K. Ramasamy, S. Mahmood, 2008 .

European Multi-Centre Study on the Use of Anti-Thymocyte Globulin in the Treatment of Myelodysplastic Syndromes.

G. Mufti, J. Cavenagh, S. Killick, 2005 .

Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation.

G. Mufti, M. Zuckerman, Z. Lim, 2007, The Journal of infection.